SEC 13F Intelligence

Parallel Advisors, LLC / HTD

Parallel Advisors, LLC’s Corcept Therapeutics Inc Position

Does Parallel Advisors, LLC own Corcept Therapeutics Inc (HTD)? Yes — 3.98M shares worth $160M (+2.88% of its 13F portfolio) as of Q2 2026.

Position Value
$160M
Q2 2026
Shares
3.98M
% of Portfolio
+2.88%
Quarters Held
29
currently held

Position History HTD

Reported value by quarter
Q2 ’19: $29,000Q2 ’19Q3 ’19: $18MQ4 ’19: $17MQ1 ’20: $17MQ2 ’20: $24MQ2 ’20Q3 ’20: $23MQ4 ’20: $41MQ1 ’21: $37MQ2 ’21: $37MQ2 ’21Q3 ’21: $34MQ4 ’21: $36MQ1 ’22: $47MQ2 ’22: $65MQ2 ’22Q3 ’22: $97MQ4 ’22: $76MQ1 ’23: $81MQ2 ’23: $83MQ2 ’23Q3 ’23: $101MQ4 ’23: $122MQ1 ’24: $101MQ2 ’24: $124MQ2 ’24Q3 ’24: $176MQ4 ’24: $193MQ1 ’25: $220MQ2 ’25: $284MQ2 ’25Q3 ’25: $322MQ4 ’25: $135MQ1 ’26: $160MQ2 ’26: $160MQ2 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q2 20263.98M$160M+2.88%
Q1 20263.98M$160M+2.88%
Q4 20253.88M$135M+2.47%
Q3 20253.87M$322M+5.89%
Q2 20253.87M$284M+5.68%
Q1 20253.97M$220M+4.95%
Q4 20243.83M$193M+4.34%
Q3 20243.81M$176M+4.15%
Q2 20243.82M$124M+3.18%
Q1 20243.72M$101M+3.38%
Q4 20233.77M$122M+3.63%
Q3 20233.72M$101M+3.38%
Q2 20233.73M$83M+2.67%
Q1 20233.72M$81M+2.72%
Q4 20223.72M$76M+3.28%
Q3 20223.77M$97M+4.45%
Q2 20222.72M$65M+2.97%
Q1 20221.94M$47M+1.87%
Q4 20211.80M$36M+1.33%
Q3 20211.73M$34M+1.37%
Q2 20211.67M$37M+1.56%
Q1 20211.56M$37M+1.76%
Q4 20201.55M$41M+2.20%
Q3 20201.29M$23M+1.39%
Q2 20201.40M$24M+1.54%
Q1 20201.41M$17M+1.35%
Q4 20191.41M$17M+1.28%
Q3 20191.28M$18M+1.55%
Q2 20192.6K$29,0000.00%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Parallel Advisors, LLC’s full portfolio or all institutional holders of HTD.